A Phase 2a Study to Assess Safety, Daily Symptoms, PK, and Biomarkers of YPL-001 in COPD Patients

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2015
This is a Phase 2a, proof-of-concept, multicenter, randomized, double-blind, double dummy, 3-treatment, parallel study, with low and high YPL 001 doses (low dose and high dose twice daily \[BID\]) and a placebo control in moderate to severe Chronic Obstructive Pulmonary Disease (COPD) patients.
Epistemonikos ID: 1c987f58e0c32d880b2203379e3f4812e6adcae6
First added on: May 12, 2024